Volume 17, Issue 5, Pages (May 2016)

Slides:



Advertisements
Similar presentations
Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.
Advertisements

Richardson PG et al. Proc ASH 2013;Abstract 535.
Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.
Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)
Volume 12, Issue 3, Pages (March 2011)
Volume 390, Issue 10101, Pages (September 2017)
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular.
Volume 12, Issue 9, Pages (September 2011)
Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase.
Volume 17, Issue 12, Pages (December 2016)
Volume 16, Issue 2, Pages (February 2015)
Volume 367, Issue 9517, Pages (April 2006)
Volume 375, Issue 9729, Pages (May 2010)
Volume 18, Issue 10, Pages (October 2017)
Volume 359, Issue 9322, Pages (June 2002)
Volume 17, Issue 12, Pages (December 2016)
Korde N et al. Proc ASH 2012;Abstract 732.
Volume 378, Issue 9791, Pages (August 2011)
Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions  Chelsea.
Oki Y et al. Proc ASH 2013;Abstract 252.
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study 
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal.
Volume 25, Issue 1, Pages (January 2017)
Volume 13, Issue 3, Pages (March 2012)
Volume 14, Issue 3, Pages (March 2013)
Volume 15, Issue 8, Pages (July 2014)
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed,
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study 
Volume 14, Issue 10, Pages (September 2013)
Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study  Dr James D Chalmers, MBChB, Brian J.
Volume 10, Issue 6, Pages (June 2009)
Volume 15, Issue 4, Pages (April 2014)
A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma  Pallawi Torka, Priyank Patel, Wei Tan,
A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer  Peter M.
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study 
Volume 384, Issue 9942, Pages (August 2014)
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors  Tomohide Tamura, MD, Hironobu Minami, MD, Yasuhide Yamada,
Dynamics of childhood growth and obesity: development and validation of a quantitative mathematical model  Dr Kevin D Hall, PhD, Prof Nancy F Butte, PhD,
Volume 390, Issue 10104, Pages (October 2017)
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study 
Volume 18, Issue 3, Pages (March 2017)
Volume 356, Issue 9241, Pages (November 2000)
Volume 12, Issue 6, Pages (June 2013)
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma  John M. Burke,
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib  Helena A. Yu,
Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy.
Volume 386, Issue 10011, Pages (December 2015)
Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with.
Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall.
Volume 388, Issue 10056, Pages (October 2016)
The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial  Dr.
Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.
Volume 376, Issue 9757, Pages (December 2010)
Volume 384, Issue 9942, Pages (August 2014)
Volume 381, Issue 9880, Pages (May 2013)
Volume 377, Issue 9771, Pages (March 2011)
Volume 361, Issue 9352, Pages (January 2003)
XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding.
Arlene Chan, Marc Buyse, Bin Yao  The Lancet Oncology 
Volume 376, Issue 9737, Pages (July 2010)
Immune-Modulating Vaccines in Non-small Cell Lung Cancer
BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study  Pasi.
Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib  Anne Lynn S. Chang, MD,
A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.
Volume 20, Issue 7, Pages (July 2019)
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK in Relapsed/Refractory SCLC 
Presentation transcript:

Volume 17, Issue 5, Pages 622-631 (May 2016) Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial  Dr Anas Younes, MD, Jesus G Berdeja, MD, Manish R Patel, MD, Ian Flinn, MD, John F Gerecitano, MD, Sattva S Neelapu, MD, Kevin R Kelly, MD, Amanda R Copeland, MSN, Amy Akins, BSN, Myles S Clancy, MBA, Lucy Gong, PharmD, Jing Wang, PhD, Anna Ma, MS, Jaye L Viner, MD, Yasuhiro Oki, MD  The Lancet Oncology  Volume 17, Issue 5, Pages 622-631 (May 2016) DOI: 10.1016/S1470-2045(15)00584-7 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile Number of patients assigned to each dose and schedule. *Although no DLT occurred within this cohort, the cohort was expanded for safety reasons. The Lancet Oncology 2016 17, 622-631DOI: (10.1016/S1470-2045(15)00584-7) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 Best response (maximum target lesion decrease) from baseline in patients with lymphoma (n=33) Maximum decrease from baseline is shown, measured by PET or CT according to the Revised Response Criteria for Malignant Lymphoma; if the lesion only increased, then the lowest measured increase is presented. Data are for the 33 patients with lymphoma in the response-evaluable dose-escalation population. Each bar represents an individual patient. *This patient had a reduction in the target lesion, but developed a concurrent new lesion and therefore was classified as having progressive disease. †This patient was shown to have a maximum target lesion reduction of about 60% on CT, but was classified as having a complete response as measured by 18F-fluorodeoxyglucose PET. ‡Other lymphomas were lymphoplasmacytic (n=3), small lymphocytic (n=3), mantle-cell (n=3), follicular (n=2), gray-zone (n=1), marginal-zone (n=1), and T-cell (n=1) lymphoma. The Lancet Oncology 2016 17, 622-631DOI: (10.1016/S1470-2045(15)00584-7) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 3 Best response (maximum decrease in serum or urine M-protein or serum free light chain) from baseline in patients with myeloma (n=4) Maximum decrease from baseline of serum or urine M-protein or serum free light chain (as applicable), which were used to assess each patient with multiple myeloma for disease response, according to the International Uniform Response Criteria for Multiple Myeloma; if only an increase was measured, then the lowest measured increase is presented. Each bar represents an individual patient. Patients 1 and 3 were assessed using serum M-protein, patient 2 was assessed using urine M-protein, and patient 4 was assessed using serum free light chain measurements. Patient 1 had achieved stable disease for 33 months, ongoing at the time of data cutoff. Patient 3 achieved stable disease for 3 months. The Lancet Oncology 2016 17, 622-631DOI: (10.1016/S1470-2045(15)00584-7) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 4 CUDC-907 and metabolite concentrations in plasma, 60 mg 5/2 dose (n=6) Cycle 1, day 15 data from six patients who received CUDC-907 at 60 mg at the 5/2 dosing schedule during the expansion phase of the trial. Datapoints show mean and error bars show SD. The Lancet Oncology 2016 17, 622-631DOI: (10.1016/S1470-2045(15)00584-7) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 5 Biomarkers of CUDC-907 activity in peripheral blood, 60 mg 5/2 dose (n=3) Data from peripheral blood mononuclear cell samples obtained from three patients during cycle 1 who received CUDC-907 at 60 mg at the 5/2 dosing schedule in the expansion phase of the trial. The ratio of phosphorylated AKT relative to unphosphorylated AKT and acetylated histone H3 relative to non-acetylated histone H3 is shown. Baseline (before dose) is before treatment on day 1 of cycle 1. Datapoints show mean and error bars show SD. Ac-H3=acetylated histone H3. pAKT=phosphorylated AKT. *Day 8 and day 15 were expected to have similar pharmacodynamic read-outs, so to reduce the volume of blood collected on the trial we only took a pre-dose sample on day 8, with the expectation that 1 h and 4 h measurements would be very similar to data from day 15. The Lancet Oncology 2016 17, 622-631DOI: (10.1016/S1470-2045(15)00584-7) Copyright © 2016 Elsevier Ltd Terms and Conditions